Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;103:1375-1377

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sugden, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sugden, P. H.

(Circulation. 2001;103:1375.)
© 2001 American Heart Association, Inc.


Editorials

Mechanotransduction in Cardiomyocyte Hypertrophy

Peter H. Sugden, DPhil

From the National Heart and Lung Institute Division, Imperial College School of Medicine, London, UK.

Correspondence to Peter H. Sugden, DPhil, NHLI Division (Cardiac Medicine), Imperial College School of Medicine, Dovehouse St, London SW3 6LY, UK. E-mail p.sugden@ic.ac.uk


Key Words: Editorials • hypertrophy • myocytes • signal transduction

The study of ventricular hypertrophy has recently been a fruitful research area. From studies principally in neonatal rat ventricular myocytes in primary culture but now increasingly in transgenic mice, the molecular mechanisms involved in this important pathophysiological adaptation are becoming clearer.1 In culture, cardiomyocyte hypertrophy is characterized by numerous transcriptional and morphological changes, including increased expression of atrial and B-type natriuretic peptides (ANP and BNP, respectively), increased ß-myosin heavy chain (ß-MHC) expression, and increased sarcomere deposition.1 Similar changes are evident in hypertrophied hearts in vivo, where increased sarcomere deposition in particular allows cardiomyocytes to accommodate demands for elevated contractile power.

Wall Strain and Left Ventricular Hypertrophy

In vivo, pathological or experimental left ventricular hemodynamic overload induces patterns of hypertrophy that can be broadly divided into concentric or eccentric. In concentric (pressure-overload) hypertrophy, peak-systolic and end-diastolic pressures are increased, but meridional ventricular wall stress is normal throughout the cardiac cycle, the additional wall stress being counterbalanced by wall thickening in the absence of chamber enlargement. In eccentric (volume-overload) hypertrophy, chamber volume is enlarged, and wall thickness is increased approximately in proportion to the increase in chamber diameter. End-diastolic pressure and wall stress are increased, but peak systolic pressure and wall stress are normal.

The orientation of cardiomyocytes in heart is primarily circumferential. Thus, cardiomyocytes from pressure- or volume-overloaded hearts differ in their relative dimensions. Cross-sectional area is proportionally expanded over length in pressure overload, whereas length is proportionally increased in volume overload. Sarcomere deposition parallel to the long axes of cells is greater in pressure overload than . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
M. A. Frias, S. Somers, C. Gerber-Wicht, L. H. Opie, S. Lecour, and U. Lang
The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis
Cardiovasc Res, October 1, 2008; 80(1): 69 - 77.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. M. D. Gonzalez, J. C. Osorio, C. Manlhiot, D. Gruber, S. Homma, and S. Mital
Hypertrophy signaling during peripartum cardiac remodeling
Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3008 - H3013.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. Sekiguchi, X. Li, M. Coker, M. Flesch, P. M Barger, N. Sivasubramanian, and D. L Mann
Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure
Cardiovasc Res, August 15, 2004; 63(3): 433 - 442.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. A. Modesti, S. Vanni, I. Bertolozzi, I. Cecioni, C. Lumachi, A. M. Perna, M. Boddi, and G. F. Gensini
Different Growth Factor Activation in the Right and Left Ventricles in Experimental Volume Overload
Hypertension, January 1, 2004; 43(1): 101 - 108.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
H. A. Baba, J. Stypmann, F. Grabellus, P. Kirchhof, A. Sokoll, M. Schafers, A. Takeda, M. J. Wilhelm, H. H. Scheld, N. Takeda, et al.
Dynamic regulation of MEK/Erks and Akt/GSK-3{beta} in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism
Cardiovasc Res, August 1, 2003; 59(2): 390 - 399.
[Abstract] [Full Text] [PDF]